Olema Oncology to Participate at Upcoming Investor Conferences

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company will present at the following upcoming investor conferences:

• Sean Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Citi’s 2023 Virtual Oncology Leadership Summit on Thursday, February 23, 2023, at 12:00 p.m. ET.
• Shane Kovacs, Chief Operating and Financial Officer, will participate in the Breast and Lung Cancer Corporate Panel at Cowen’s 43rd Annual Healthcare Conference on Tuesday, March 7, 2023, at 10:30 a.m. ET in Boston, MA.

A live webcast of these events will be available under the News & Events section of Olema’s Investor Relations website at www.olema.com and will be archived for at least 30 days.

About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. 

IR Contact:Courtney Dugan, Vice President, Investor Relations and Communications [email protected]

Media Contact:Ignacio Guerrero-Ros, Ph.D., Russo Partners646-942-5604[email protected]

You May Also Be Interested In

• Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
• Olympia Financial Group Inc. Announces June Dividend
• POP Biotechnologies Secures Up to $9.7 Million in CEPI Funding